Meera Varman, MBBS

Professor

Department of Pediatrics

Phone402-280-1238
Emailmeeravarman@creighton.edu
Websitehttp://medschool.creighton.edu/faculty/varman/contact/

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

External positions

University of South Alabama

Fingerprint

Dive into the research topics where Meera Varman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

3 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

310 Citations
9 h-Index
28 Article
3 Review article
2 Conference contribution
2 Letter
More
- 1 Comment/debate
- 1 Conference article

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
Olsson, S. E., Restrepo, J. A., Reina, J. C., Pitisuttithum, P., Ulied, A., Varman, M., Van Damme, P., Moreira, E. D., Ferris, D., Block, S., Bautista, O., Gallagher, N., McCauley, J. & Luxembourg, A., Dec 2020, In: Papillomavirus Research. 10, 100203.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention
Varman, M., Sharlin, C., Fernandez, C., Vasudevan, J. & Wichman, C., Jan 24 2018, (Accepted/In press) In: Journal of Community Health. p. 1-4 4 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
Kovac, M., Kostanyan, L., Mesaros, N., Kuriyakose, S. & Varman, M., May 9 2018, In: Human Vaccines and Immunotherapeutics. 14, 8, p. 1977-1986 10 p.
Research output: Contribution to journal › Article › peer-review
7 Scopus citations
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial
The MMR-161 Study Group, Sep 11 2018, In: Vaccine. 36, 38, p. 5781-5788 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations
Sharing antimicrobial reports for pediatric stewardship (SHARPS): A quality improvement collaborative
SHARPS Collaborative, May 15 2018, In: Journal of the Pediatric Infectious Diseases Society. 7, 2, p. 124-128 5 p.
Research output: Contribution to journal › Article › peer-review
14 Scopus citations

External positions

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

Human Papilloma Virus Vaccination Among Adolescents in a Community Clinic Before and After Intervention

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial

Sharing antimicrobial reports for pediatric stewardship (SHARPS): A quality improvement collaborative